eltrombopag articles & resources on Made-in-China.com

GSK Has Received Approval for Its Platelet-Boosting Drug Revolade in The Treatment

Jun 14, 2013

GlaxoSmithKline has received approval from the UK’s National Institute for Health and Clinical Excellence (NICE), for its platelet-boosting drug Revolade in the treatment of adult bleeding disorder, chronic immune (idiopathic) ...

Tags: Blood Disorder Treatment, Medicine

GSK Gained FDA Priority Review Status for The Supplemental New Drug Application

Dec 7, 2012

GlaxoSmithKline (GSK), Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. ...

Tags: GlaxoSmithKline, GSK, promacta, thrombocytopenia

GSK Promacta Won FDA Approval as Thrombocytopenia Therapy in Chronic Hepatitis C Patients

Nov 20, 2012

GlaxoSmithKline's (GSK) Promacta has won FDA approval as thrombocytopenia therapy in chronic hepatitis C patients. Promacta, brand name of eltrombopag in the US, will enable thrombocytopenia patients suffering from chronic hepatitis C ...

Tags: FDA approval, thrombocytopenia therapy, chronic hepatitis C

GlaxoSmithKline Submitted Regulatory Applications for Eltrombopag in US, Europe

Jun 4, 2012

Ligand Pharmaceuticals partner GlaxoSmithKline has submitted regulatory applications in the US and European Union for the use of eltrombopag (Promacta/Revolade) to increase platelet counts in patients with hepatitis C. A supplemental ...

Tags: regulatory application, eltrombopag, hepatitis C

eltrombopag

GSK Has Received Approval for Its Platelet-Boosting Drug Revolade in The Treatment

GSK Gained FDA Priority Review Status for The Supplemental New Drug Application

GSK Promacta Won FDA Approval as Thrombocytopenia Therapy in Chronic Hepatitis C Patients

GlaxoSmithKline Submitted Regulatory Applications for Eltrombopag in US, Europe

Related Products